Zevra to finish what Orphazyme started: "We have set ourselves up for success"
Zevra Therapeutics, which bought Orphazyme’s failed rare disease candidate last year, has what the embattled developer needed: time and money.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
Orphazyme’s former drug candidate arimoclomol had already been rejected by the US Food and Drug Administration (FDA) – and was likely about to be rejected by the European Medicines Agency (EMA) as well, before the developer retracted its marketing application.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
